Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that it has entered into a strategic collaboration with Thermo Fisher Scientific to advance fundamental knowledge of cell therapy industrialization and to improve quality control of the end-to-end supply chain. As quoted in the press release: The collaboration combines Thermo Fisher’s experience … Continued
The post Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific appeared first on Investing News Network.
Original Article: Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific